Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease: A Multicenter, Prospective, Randomized Controlled Study
Conditions
Interventions
Dulaglutide
SGLT2i
+1 more
Start Date
May 1, 2026
Primary Completion Date
April 1, 2027
Completion Date
July 1, 2027
Last Updated
April 22, 2026
NCT07321678
NCT07314684
NCT07237451
NCT06293417
NCT07172997
NCT06733805
Lead Sponsor
First Affiliated Hospital of Wannan Medical College
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions